EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

LAG ‐3—An incompletely understood target in cancer therapy

Judith Leitner iD, Katharina Aigner-Radakovics iD, Peter Steinberger iD

The FASEB Journal · 2024

DOI: 10.1096/fj.202401639r ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The FASEB Journal, 2024. Verfasst von Judith Leitner und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division for Immune Receptors and T Cell Activation, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical Univer…. Hauptthemen laut MEDLINE: Lymphocyte Activation Gene 3 Protein, Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 121 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Austrian Science Fund (FWF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

LAG‐3 is a member of the immunoglobulin superfamily expressed on activated T cells, but also on other immune cells. It has significant homology to CD4. Both molecules have four extracellular Ig‐like domains with similar structural motifs but the sequence identity between LAG‐3 and CD4 is low. Furthermore, unlike CD4 LAG‐3 restrains T cell responses and antibodies targeting this receptor are emerging drugs in cancer immunotherapy. A combination of LAG‐3 and PD‐1 antibodies has already been approved for the treatment of metastatic melanoma. Despite this success, its biology is still not well understood. Here we summarize the current knowledge on expression, ligands, and function of LAG‐3. We point to the differences between LAG‐3 and other inhibitory immune checkpoints and describe obstacles to study the role of this receptor in T cell activation processes. Finally, we discuss future directions for scientific efforts to come to a more complete understanding of the biology of this eminent immune checkpoint.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphocyte Activation Gene 3 ProteinNeoplasmsHumansAnimalsAntigens, CDImmunotherapyImmune Checkpoint InhibitorsLymphocyte Activation

Stichwörter der Autor:innen

LAG‐3T cell regulationimmune checkpointsimmunotherapyinhibitory receptors

Substanzen

Lymphocyte Activation Gene 3 ProteinAntigens, CDLag3 protein, humanImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Division for Immune Receptors and T Cell Activation, Institute of Immunology, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, Vienna, Austria.

ORCID-Profile: Judith Leitner, Katharina Aigner-Radakovics, Peter Steinberger

Förderung

  • Austrian Science Fund (FWF)

Zitieren

APA

Leitner, J., Aigner-Radakovics, K., & Steinberger, P. (2024). LAG ‐3—An incompletely understood target in cancer therapy. The FASEB Journal. https://doi.org/10.1096/fj.202401639r

Vancouver

Leitner J, Aigner-Radakovics K, Steinberger P. LAG ‐3—An incompletely understood target in cancer therapy. The FASEB Journal. 2024. doi:10.1096/fj.202401639r

BibTeX
@article{Leitner2024,
  author = {Leitner, Judith and Aigner-Radakovics, Katharina and Steinberger, Peter},
  title = {LAG ‐3—An incompletely understood target in cancer therapy},
  journal = {The FASEB Journal},
  year = {2024},
  doi = {10.1096/fj.202401639r}
}
Kostenlos starten →